The endocannabinoid system in female reproduction: from ovary to uterus

Endocannabinoid signaling in female reproduction

The endocannabinoid system (ECS) is active in female reproductive tissues, not only in the nervous system. Components have been described in the ovary, fallopian tubes, endometrium, uterus and placenta. Their presence helps explain growing interest in reproductive biology, but does not establish that taking cannabis improves fertility.

Anandamide, 2-AG and the enzymes that regulate them

The body produces its own lipid messengers, including anandamide (AEA) and 2-AG. CB1 and CB2 receptors, enzymes involved in anandamide synthesis, such as NAPE-PLD, and breakdown, such as FAAH contribute to tightly regulated signaling. Location, concentration and timing matter: more cannabinoid activity is not automatically better.

Follicles and ovulation

Studies of human ovarian tissue and follicular fluid have identified ECS components in developing follicles and the corpus luteum. Associations between anandamide concentrations and follicular maturity are biologically intriguing. An association alone does not prove that changing these concentrations will improve ovulation outcomes.

From the fallopian tube to implantation

Embryo transport and the uterine window of implantation are precisely timed events. Experimental work suggests that endocannabinoid signaling can participate in these stages. Disrupting signaling, including excessive activation, may be harmful in some models. This is why the topic demands particular caution when attempting conception.

Hormones and changing cycles

ECS activity may interact with estrogen and progesterone signaling, and its components can vary during the menstrual cycle. This supports studying links with conditions such as endometriosis and pelvic pain, but it is not proof of an ECS deficiency in an individual patient.

What this means for treatment and pregnancy

Clinical evidence does not support cannabis as a treatment to improve fertility, implantation or pregnancy outcomes. Cannabis use is discouraged when planning pregnancy, during pregnancy and while breastfeeding. Anyone using cannabis or other cannabinoid products should discuss a plan for their symptoms and medicines with a qualified clinician before conception.

Key conclusion

The ECS in female reproduction is an established field of biological research linking reproductive biology, pain and immunity. It should be understood as a carefully balanced physiological system, not a reason to self-medicate with cannabis.

Source article and references

This article is an editorial adaptation of the Hebrew original.

Read the Hebrew source article ↗

ACOG guidance on cannabis, pregnancy and lactation ↗